Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

1.350 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 10, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Abeona Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Thinking about buying stock in GameStop, AMC Entertainment, Meredith Corp, Sundial Growers, or Abeona Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, MDP, SNDL, and ABEO. 
From PR Newswire
Thinking about buying stock in Motus GI, Abeona Therapeutics, Skillz Inc, Marker Therapeutics, or Nikola Corp?
InvestorsObserver issues critical PriceWatch Alerts for MOTS, ABEO, SKLZ, MRKR, and NKLA. 
From PR Newswire
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Starg
From GlobeNewswire News Releases
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products 
From GlobeNewswire News Releases
Abeona Therapeutics Inc. (NASDAQ:ABEO) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc. 
From SBWire - Latest Press Releases
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
Refreshed board to bring fresh perspectives, relevant expertise and diverse experience 
From GlobeNewswire News Releases
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
CEO appointment provides continuity and reflects company’s demonstrated strong operational performance 
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene
From GlobeNewswire News Releases
Thinking about buying stock in Heat Biologics, Zosano Pharma, Glu Mobile, AzurRx BioPharma, or Abeona Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for HTBX, ZSAN, GLUU, AZRX, and ABEO. 
From PR Newswire
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
From GlobeNewswire News Releases
Abeona Therapeutics Reports Third Quarter Financial Results
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
From GlobeNewswire News Releases
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
From GlobeNewswire News Releases
Abeona Therapeutics Announces Leadership and Board Transitions
From GlobeNewswire News Releases
Abeona Therapeutics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
From GlobeNewswire News Releases
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
From GlobeNewswire News Releases
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
From GlobeNewswire News Releases
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs 
From GlobeNewswire News Releases
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
From GlobeNewswire News Releases
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
From GlobeNewswire News Releases
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
From GlobeNewswire News Releases
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
From GlobeNewswire News Releases
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
From GlobeNewswire News Releases
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.